Rubicon Research Acquires 85% Stake in Arinna Lifesciences

Rubicon Research Limited acquires 85% equity ownership in CNS-focused Arinna Lifesciences Limited for approximately ₹175.92 Crores.
Transaction values Arinna at ₹200 Crores enterprise value on cash and debt free basis, with provisional revenue of ₹56.7 Crores for 9M Dec 2025.
Acquisition provides Rubicon access to Indian CNS market with over 60 brands and 4,000+ prescribers through Arinna's established distribution network.
Founder Vivek Seth retains 15% ownership and continues as Managing Director, with transaction closure expected within 30 days.